MedTrace Logo

Empagliflozin and Hepatic Glucose Metabolism

NCT03193684 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-08-28

Study results available
· View outcomes & findings →

Summary

the aim of this study is to examine the role of autonomic nervous system in the increase in hepatic glucose production in response to glucosuria caused by inhibition of renal glucose uptake

Conditions

  • Hepatic Glucose Metabolism

Interventions

DRUG

Empagliflozin 25 MG

subjects will receive daily dose of 25mg of empagliflozin for 3 months

DRUG

Control

Placebo

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Muhammad Abdul-Ghani, MD, PhD · Diabetes Division, UTHSCSA

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-20
Primary Completion
2023-01-30
Completion
2024-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193684 on ClinicalTrials.gov